Showing results (61-70 of 70) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
British Journal of Haematology|March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 studyMichael Wang, Leslie L Popplewell, Robert H Collins, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani, Fangxin Hong, Richard I Fisher, et al.British Journal of Haematology|September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraCatherine S Diefenbach, Hailun Li, Fangxin Hong, et al.Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.British Journal of Clinical Pharmacology|July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunctionNaoko Takebe, Jan H Beumer, Shivaani Kummar, et al.Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.The New England Journal of Medicine|October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's LymphomaAlex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.Pageof 7